Mystic Pharmaceuticals Receives Notices of Allowance From Japan and China on Drug Delivery Platform Technologies

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has received Notices of Allowance from the China Patent Office for its “Deep Draw Container Forming Method” (invention number ZL200880106965.1) and the Japan Patent Office for its “Combination Unit Dose Dispensing Container” (application number 2010-508588) patent applications. Mystic’s VersiDoser® and VRx2™ delivery technologies are used in combination with drugs and biologics to develop therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations. Timothy Sullivan, Mystic’s President and CEO, stated that, “Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products. Japan and China along with several other global markets are high priority strategic opportunities for Mystic enhanced pharmaceutical drug/device combined products. These latest international patents reflect our long term commitment to developing the global market opportunity for our technology and products.” Mystic’s VersiDoser® and VRx2™ delivery platforms utilize novel unit dose packaging and patient-centric dispensers that can be configured for precision self-administration of therapeutics for ophthalmic, systemic nasal, nose to brain, sublingual, oral and dermal applications.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC